Navigation Links
NxStage® Names Michael Miller, Jr. President, International
Date:4/27/2011

LAWRENCE, Mass., April 27, 2011 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Michael Miller, Jr., former Senior Vice President and General Manager of the Cardiac Care Business at Philips Healthcare, has joined the NxStage senior management team in the newly-created position of President, International.

Miller will be responsible for advancing the Company's international growth plans in the European Union (EU), the Middle East, and Asia-Pacific. "I believe NxStage has a tremendous opportunity to expand patient access to its life-changing products across the globe," said Miller. "This is a remarkable company that I believe has the potential to truly transform renal care on an even broader scale.  I am excited to join NxStage and to bring my experience in international medical device sales and business development to its important mission."

During ten years at Philips, Miller held leadership roles in marketing and general management for a variety of global businesses.  In his most recent role as Senior Vice President and General Manager of the Philips Cardiac Care Business he led worldwide expansion efforts for four medical device businesses across new and emerging markets. Prior to Philips, Miller was Director and Vice President of U.S. Sales for Advanced Sterilization Products, a division of Johnson & Johnson Medical, Inc., as well as Director of International and New Business Development- Worldwide.  He also held various positions with Hewlett Packard Medical Products Group that included responsibilities for domestic and international product marketing in several product areas.  Miller holds an MBA from Harvard Graduate School of Business Administration and a BA in economics from Yale University.

"Mike's strong track record in global sales over three decades for some of the premier leaders in our industry speaks for itself," said Jeffrey Burbank, Chief Executive Officer of NxStage Medical, Inc. "NxStage is very pleased that such a proven leader shares our vision and excitement to make a life-changing difference in renal care for patients with ESRD.  I believe Mike's skills and experience will be invaluable to us as we advance our international expansion strategy."

About NxStage

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. The forward-looking statements in this release include statements as to NxStage's ability to expand patient access to its products worldwide and NxStage's ability to transform renal care worldwide. Results may differ materially from those indicated by these forward-looking statements as a result of various important factors including customer demand for our products in the European Union (EU), the Middle East and Asia-Pacific and other factors  that are discussed in NxStage's Annual Report on Form 10-K for the year ended December 31, 2010 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact:
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
ir@nxstage.com
978-332-5923


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage® to Report First Quarter Fiscal 2011 Financial Results
2. New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period
3. In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis
4. NxStage® Reports Fourth Quarter and Full-Year 2010 Financial Results; Revenue Growth Exceeds Company Guidance
5. NxStage® to Report Fourth Quarter and Full Year 2010 Financial Results
6. NxStage® Appoints Nancy J. Ham to Its Board of Directors and Announces Resignation of Board Member Jonathan T. Silverstein
7. First NxStage® Home Hemodialysis Patients Celebrate Seven-Year Anniversary
8. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
9. Cetero Research Names 25-Year Industry Veteran James Dixon to Head Quality and Compliance
10. BridgePoint Medical Names Industry Veteran as Chief Executive Officer
11. Survey Sampling International Names Chris DeAngelis to Head New SSI Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Alzheimer Diagnostic Tests - Medical ... Medical Devices sector report , "Alzheimer Diagnostic Tests ... overview of Alzheimer Diagnostic Tests currently in pipeline ... the pipeline products with comparative analysis of the ... reviews major players involved in the pipeline product ...
(Date:2/8/2016)... LONDON , Feb.8, 2016 Aesthetic Devices ... GlobalData,s Medical Devices sector report, "Aesthetic Devices - Medical ... Devices currently in pipeline stage. This ... secondary and primary research by GlobalData,s team of industry ... be removed or altered based on the availability and ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Local insurance agency Dennis Fuller & ... has initiated a fundraiser for a two year old little girl named Bella, ... To support this beautiful child who is facing life’s journey without her loving ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... frequently. While a significant number of women and men with eating disorders report ... itself, that best predicts the development of an eating disorder. , At ...
(Date:2/8/2016)... ... 2016 , ... Discover the Rocky Mountain region’s longest running and impressive garden ... Attendees also get to see the most incredible gardens and home improvement experts that ... the Colorado Convention Center - 700 14th St. Denver CO, is an exciting event ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... share this important news! AHCC and the Home Health and Hospice ICD-10 Transition ... designee for official ICD coding guidance and clarifications, to address concerns over the ...
Breaking Medicine News(10 mins):